A $205 million agreement announced Tuesday, Nov. 10, would move Scholar Rock’s priority review voucher to BioNTech for a future cancer application seeking faster review by the U.S. Food and Drug Administration (FDA).
BioNTech said the application would involve a candidate from its more advanced oncology program. The voucher allows a single chosen filing to receive priority handling, with a shorter target period for FDA review.
An earlier Ultragenyx voucher sale was valued at $203 million, $2 million below the Scholar Rock agreement. The agreement pairs Scholar Rock as seller with BioNTech as the intended user.
Among the remaining requirements is clearance under the Hart-Scott-Rodino Antitrust Improvements Act. BioNTech is due to pay when the deal closes.
